Skip to main content
OpenTrials
Completed

NCT Number: NCT01010009

The Cognitive and Cerebral Blood Flow Effects of Resveratrol

Research shows that resveratrol is able to induce vasodilation (and therefore blood flow) by interacting with nitric oxide (NO). Research also shows that acute administration of metabolic substrates, like oxygen and glucose, can enhance aspects of cognitive performance in young, healthy humans. The aim of this investigation was to determine if the consumption of resveratrol could modulate cerebral blood flow and if this in turn could influence cognitive performance by increasing access to blood borne metabolic fuel. Results showed that compared to placebo, after consuming 500mg pure trans-resveratrol, levels of total haemoglobin were significantly higher in the frontal cortex of young, healthy participants during cognitive task completion. Cognitive performance was not effected.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive and Cerebral Blood Flow Effects of Resveratrol

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northumbria University

Newcastle upon Tyne, NE1 8ST, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male/female,
  • Healthy
  • Age 18-35 years old
  • Non smoker
  • Proficient in English
  • Not taking any herbal or prescription medications
  • Not pregnant
  • Does not drink more than 6 cups of coffee per day

Exclusion criteria

  • Suffered a head injury, neurological disorder or neuro-developmental disorder
  • Food allergies/intolerances

Treatment and study plan

Trans- resveratrol

Dietary Supplement

All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.

Other names: Transmax from Biotivia.

Placebo (silica)

Other

All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.

Other names: Pharmaceutical grade silica

Primary outcomes

  1. Modulation of Levels of Total Haemoglobin

    Time frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins)

    This outcome measure provides the change from baseline values (in µmol/L) of total levels of haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).

  2. Modulation of Deoxygenated Levels of Haemoglobin

    Time frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins)

    This outcome measure provides the change from baseline values (in µmol/L) of levels of deoxygenated haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).

Secondary outcomes

  1. Number of Participants With Significant Modulation of Cognitive Performance

    Time frame: 46-81 mins post dose

    This outcome measure assessed any significant modulation of cognitive task performance during the 46-81 min post dose period. The cognitive tasks utilized were cognitively demanding computer based, numerical tasks which assessed working memory. Significant modulation is defined as significant difference between baseline and post-dose task performance.

Sponsors and collaborators

Lead sponsor

Northumbria University

Other

Registry information

Official study title

Effects of Resveratrol on Cerebral Blood Flow Parameters and Cognitive Performance in Humans: a Double-blind, Placebo-controlled, Crossover Investigation

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Nov 9, 2009
Registry last updated
May 23, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.